

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.*

(a joint stock limited company established in the People's Republic of China with limited liability)

(Stock Code: 8058)

**PROPOSED TRANSFER OF LISTING
FROM THE GROWTH ENTERPRISE MARKET TO
THE MAIN BOARD OF
THE STOCK EXCHANGE OF HONG KONG LIMITED**

Financial Adviser to the Company



The Board is pleased to announce that the Company has submitted an application to the Stock Exchange for the Transfer of Listing on 21 December 2015 under Chapter 9A of the Main Board Listing Rules.

The Board believes that the proposed Transfer of Listing will enhance the profile and public recognition of the Company as well as increase the trading liquidity of the Shares. The Board considers that the proposed Transfer of Listing will be beneficial to the future growth and business development of the Group as well as its financing flexibility.

Shareholders and potential investors should be aware that the implementation of the proposed Transfer of Listing is subject to, among others, the granting of relevant approval by the Stock Exchange. There is no assurance that permission will be obtained from the Stock Exchange for the proposed Transfer of Listing. Accordingly, the proposed Transfer of Listing may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

* *For identification purpose only*

References are made to the Company's announcements of the Company dated 4 February 2013 and 7 May 2014 in relation to the previous proposed transfer of listing as well as to the announcement dated 22 June 2015 and the circular dated 30 October 2015 in relation to the new proposed transfer of listing of the Shares from the GEM to the Main Board (the "**Transfer of Listing**"). Unless otherwise stated herein, all capitalized terms used in this announcement shall have the same meaning ascribed thereto in the Circular.

The Board is pleased to announce that the Company has submitted an application to the Stock Exchange for the Transfer of Listing on 21 December 2015 under Chapter 9A of the Main Board Listing Rules.

The Company has been listed on GEM since 9 December 2005. The Group is principally engaged in the manufacturing and trading of system specified medicines, antibiotics medicines and other system specified medicines.

The Board believes that the proposed Transfer of Listing will enhance the profile and public recognition of the Company as well as increase the trading liquidity of the Shares. The Board considers that the proposed Transfer of Listing will be beneficial to the future growth and business development of the Group as well as its financing flexibility. No change in the nature of the business of the Group is contemplated by the Board following the proposed Transfer of Listing. The proposed Transfer of Listing will not involve the issue of any new Shares by the Company.

The Company has appointed LY Capital Limited as its financial adviser in relation to the proposed Transfer of Listing.

The Board would like to emphasise that the definitive timetable for the proposed Transfer of Listing has yet to be finalised. Further announcement(s) will be made by the Company to keep the shareholders and potential investors of the Company informed of the progress of the proposed Transfer of Listing as and when appropriate.

Shareholders and potential investors should be aware that the implementation of the proposed Transfer of Listing is subject to, among others, the granting of relevant approval by the Stock Exchange. There is no assurance that permission will be obtained from the Stock Exchange for the proposed Transfer of Listing. Accordingly, the proposed Transfer of Listing may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Liu Baoqi
Chairman

PRC, 21 December 2015

As at the date of this announcement, the Board comprises 11 Directors, of which Mr. Liu Baoqi (劉保起), Ms. Li Minghua (李明華), Mr. Han Fengsheng (韓風生), Mr. Chen Yu (陳雨) and Mr. Liu Zhenteng (劉振騰) are executive Directors; Mr. Yin Chuangui (尹傳貴) and Mr. Liu Zhenhai (劉振海) are non-executive Directors and Mr. Foo Tin Chung, Victor (傅天忠), Mr. Fu Hongzheng (付宏征), Prof. Chen Yun Zhen (陳允震) and Prof. Du Guanhua (杜冠華) are independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement in this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at <http://shandongluoxin.quamir.com>.